Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT01417455 |
| Other study ID # |
BCRAAS |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
N/A
|
| First received |
August 15, 2011 |
| Last updated |
December 13, 2011 |
| Start date |
January 2012 |
| Est. completion date |
January 2015 |
Study information
| Verified date |
December 2011 |
| Source |
Instituto de Medicina Molecular |
| Contact |
João Fonseca, MD, PhD |
| Phone |
00351969049532 |
| Email |
jefonseca[@]netcabo.pt |
| Is FDA regulated |
No |
| Health authority |
Portugal: National Pharmacy and Medicines Institute |
| Study type |
Observational
|
Clinical Trial Summary
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are characterized by chronic
systemic inflammation and share common pathogenic pathways. In both diseases, cytokines like
TNF and IL-17, known for their pro-inflammatory and osteoclastogenic effects, are relevant
players, however, while RA is characterized by bone erosions, AS favors bone overgrowth.
Understanding this paradox may hold the key for a better management of both diseases. Our
hypothesis is that there are differences in the cellular environment and intracellular
signaling between AS and RA. To test this hypothesis we will evaluate the cytokine milieu,
the kinetics of bone cells differentiation and their activity in untreated and
immunosuppressed RA and AS patients. We will also perform the same observations in patients
exposed to targeted treatments.
Description:
Objectives:
1. Assess the influence of immune system cells in the modulation of bone turnover in
patients with RA, AS and healthy donors (Task 2).
2. Analyze the osteoclast precursors and their differentiation into fully functional
osteoclasts in a subgroup of patients with RA, AS and healthy donors (Task 3, 4 and 6).
3. Study osteoblast differentiation potential and activity in a subgroup of patients with
RA and AS (Task 5 and 6)
4. Assess the effect of the therapy on bone cell differentiation and function in a
subgroup of patients with RA and AS treated with TNF-blockers (Task 2, 3, 4 and 5).
Work program and timetable Starting date: July 2011. Finishing date: July 2013 Task 1 -
Patients Patients with RA diagnosis (according to the revised American Rheumatism
Association criteria, 1988) and AS diagnosis (according to the European Spondyloarthropathy
Study Group criteria, 1991) followed up in the Rheumatology and Bone and Metabolic Diseases
Department of Hospital de Santa Maria (HSM) will be recruited for this study. Twenty-five
patients with active RA (Disease Activity Score 28 (DAS28)>3.2) and 25 patients with active
AS (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)>4) will be included in the
study. Fifteen healthy donors, sex and age matched, will be recruited and used as a control
group.
Patients will be submitted to a clinical protocol that includes information on sex, age,
disease duration, previous therapies, presence of rheumatoid factor and anti
cyclic-citrullinated peptide antibodies, HLA-B27 status, DAS28 score and Health Assessment
Questionnaire - HAQ (for RA patients), BASDAI, Maastricht Ankylosing Spondylitis Enthesitis
Score (MASES), Bath Ankylosing Spondylitis Functional Index - BASFI (for AS patients) and
Ankylosing Spondylitis Disease Activity Score (ASDAS). Blood will be collected from patients
before starting treatment with glucocorticoids and disease-modifying anti-rheumatic drugs
(DMARDs: methotrexate, sulphasalazine and leflunomide) and 3 months after reaching a stable
dose of these drugs. For those that latter on start TNF-blockers blood samples will be
collected after 6 months of starting therapy. Because it is expected that only a minority of
this initial cohort will need to be treated with TNF antagonists, a second group of 25 RA
and 25 AS patients, selected for starting TNF antagonists, will be assessed before starting
the drug and 6 months later.
Written informed consent will be obtained from all patients prior to any protocol-specific
procedure and this study will be conducted in accordance with the regulations governing
clinical trials such as the Declaration of Helsinki, as amended in Tokyo (2004). This study
was approved by HSM Ethics Committee.
All the procedures in the following tasks will be performed in RA and AS patients (serum and
blood) and healthy donors (serum), unless stated differently.
Task 2 - Study of the inflammatory stimuli and bone turnover markers Sub-populations of
immune system cells (neutrophils, B and T cell subpopulations, including Th17 cells) will be
analysed for surface RANKL expression by flow cytometry.
Pro-inflammatory cytokines like IL-1β, IL-6, IL-17A, IL-20, IL-23, TNF and bone modulating
proteins (OPG, sRANKL, sclerostin and dickkopf-1) will be quantified by ELISA. Bone
degradation enzymes like tartrate-resistant acid phosphatase (TRAP)5b and bone turnover
markers like type I collagen carboxyterminal cross-linked telopeptide (ICTP) and procollagen
type 1 amino-terminal propeptide (P1NP) will also be studied.
The data obtained from flow cytometry experiments and protein quantification will be
compared between diseases before and after treatment and with healthy donors. This will
allow us to understand the disease-specific differences in the systemic and local
inflammatory environment in untreated patients and the effect of the different therapies
over this same environment.
Task 3 - Analysis of osteoclast precursors and their differentiation into functional
osteoclasts Circulating CD14+ cells will be characterized by analysing markers like HLA-DR,
CD16, CD86, CD11b and CD62L, as well as osteoclast differentiation-associated proteins, such
as the surface integrin CD51/CD61 (αVβ3 integrin), RANK and the calcitonin receptor by flow
cytometry..
In order to fully characterize the osteoclasts precursors, the expression of
osteoclast-related genes like DCSTAMP, MITF, CTSK, TRACP and ATP6v0d2 in CD14+ cells will be
assessed by RT-qPCR. The results obtained will be normalized with the housekeeping genes
beta glucuronidase (GUSB) and phosphomannomutase-1 (PMM1).
Data obtained from flow cytometry and gene expression experiments will be compared between
treated and untreated patients and with healthy donors. This task will provide us
quantitative information on the disease-specific changes of the CD14+ monocytes
subpopulation and it will allow us to understand the effect of therapy in the circulating
precursor cells.
Task 4 - Function and cellular dynamics of the differentiated osteoclasts The isolated CD14+
monocytes will be cultured for 21 days in the presence of M-CSF and hrRANKL at 37º, 5% CO2
in multiwell culture plates.
Osteoclasts will be analyzed at days 7, 14 and 21 of culture to assess cellular dynamics.
Expression of osteoclast-specific genes will be analyzed at these time-points by RT-qPCR
(see Task 3). Flow cytometry analysis will be performed to assess the CD51/CD61 and RANK
surface expression. Data obtained during time points (days 7, 14 and 21) from patients and
healthy controls will be compared with the same data obtained from the precursor cells.
At the 21st culture day cells will be used in two functional assays: TRAP staining and
resorption assay. In the TRAP staining assay we will assess the number of osteoclasts formed
in culture by counting TRAP-positive multinucleated cells with more than 3 nuclei
(osteoclasts). Comparison of this value with nuclei count in CD14+ monocytes in culture
plates will allow us to determine the fusion index of these precursors. The resorption assay
is carried by culturing monocytes over bone slices and allows us to measure the resorption
activity of functional osteoclasts. This will be measured by image analysis of the bone
slices stained with toluidine-blue where the resorbed area acquires a blue to purple color.
The analysis of the fusion rate of precursors and of the osteoclast resorbed area will allow
us to identify differences in osteoclast function between RA and AS patients and healthy
donors.
Both monocytes and osteoclasts will be studied regarding the RANK/RANKL and the αVβ3
integrin and c-fms signalling pathways that lead to the recruitment and activation of TRAF6,
tyrosine kinase Src and ERK1/2 activating NF-kB and other transcription factors. These
signalling pathways will be studied using the Luminex xMAP platform with EpiQuant Cell
Signalling Assays (Millipore). Comparison of the results from untreated patients and
controls will allow us to understand if there is an impairment in osteoclast
differentiation/activation classical pathways in AS as compared to RA.
The results obtained from treated and untreated patients will provide insight on the action
of the therapies on osteoclast differentiation and function. Comparing overall results from
untreated patients and healthy donors will allow us to understand key differences between
osteoclast differentiation and activation in these pathologies.
Task 5 - Function and cellular dynamics of osteoblasts In a subgroup of RA and AS patients
submitted either to hip replacement or cervical surgery osteoblast differentiation will be
studied. Immediately after surgery, a small piece of trabecular bone (1cm3) will be
extracted from the sample in order to isolate the osteoblasts. After isolation, osteoblasts
will be cultured in DMEM supplemented with vitaminD3 (10-8M) and cells will be studied at
80% confluence. Osteoblasts' function will be studied in vitro by MTT assay (cell
proliferation), alkaline phosphatase staining and mineralization nodules formation. Cells
will be also used for RNA extraction and gene expression analysis Specific genes that encode
proteins such as osteopontin, collagen type I, osteocalcin, alkaline phosphatase, RANKL,
osteoprotegerin, runx2 and osterix will be analyzed to characterize the isolated cells.
These results will allow us to understand the differences in osteoblast differentiation and
activity between diseases.
Task 6 - Bone gene expression assays In a subgroup of RA and AS patients submitted either to
hip replacement or cervical surgery we will frozen bone samples at -80ºC. With the bone
still frozen, a small sample of trabecular bone will be reduced to fine powder in a
cryogenic mill and the RNA extraction will be performed using TRIzol reagent. The resulting
RNA will be assessed for its integrity and quantified in a Bioanalyser. Therefore, the RNA
extracted will be the total of RNA present in bone, from blood, osteoblasts, osteoclasts,
osteocytes, adipocytes and bone marrow cells.
The gene expression both in the bone microenvironment and in the cells from the in vitro
studies will be evaluated by RT-PCR. Specific genes that encode proteins both from
osteoblasts and osteoclasts such as osteopontin, collagen type I, osteocalcin, alkaline
phosphatase, RANKL, osteoprotegerin, runx2, osterix, cathepsin K, beta3 integrin subunit,
calcitonin receptor, ATPase subunit d2, TRAF6, RANK, TRAP, the co-receptors OSCAR and
TREM-2, among others, will be studied. Osteocytes' activity will also be assessed by the
expression of specific genes, SOST, Dkk1, DMP-1, Phex, E11 antigen, MEPE and CD44. The genes
that code the inflammatory cytokines IL-1, IL-6, IL-17 and TNF will also be studied.
In order to assess the PCR efficiency, standard curves will be built from RNA extracted from
frozen bone samples from individuals with normal bone mineral density and with no other
disease that could have influence in bone metabolism. The osteoclast, osteoblast and
osteocyte genes of interest will be quantified by the standard curve method.
The RNA expression study on the bone samples will allow us to understand the local cell
activity and it characterize bone cells and their function in a disease context.
